TREVENA,INC. (NASDAQ:TRVN) Files An 8-K Other Events
Item 8.01. Other Events.
On January30, 2019, Trevena,Inc. (the “Company”) issued a press release announcing that it entered into securities purchase agreements dated January 29, 2019 (the “Purchase Agreements”) with two healthcare–focused institutional investors (the “Purchasers”). to the terms of the Purchase Agreements, the Company agreed to sell to the Purchasers in a registered direct offering an aggregate of 10,000,000 shares of its common stock at a purchase price of $1.00 per share. A copy of the press release is filed as Exhibit99.1 to this Current Report on Form8-Kand is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
|
Number |
Description |
|
99.1 |
Press Release dated January30, 2019 |
TREVENA INC Exhibit
EX-99.1 2 a19-3646_1ex99d1.htm EX-99.1 Exhibit 99.1 Trevena Announces $10 Million Registered Direct Offering of Common Stock CHESTERBROOK,…
To view the full exhibit click here
About TREVENA,INC. (NASDAQ:TRVN)
Trevena Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. Its TRV130 is a Mu-receptor G protein Pathway Selective (Mu-GPS) modulator that activates G protein. Its TRV250 is a small molecule G protein biased ligand of the d-opioid receptor in preclinical development. Its TRV734 is a small molecule Mu-GPS that it has discovered and has developed through Phase I as a first-line, orally administered compound for the treatment of moderate to severe acute and chronic pain. Its TRV027 is a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R). In addition to these three product candidates, the Company has identified and has completed the Phase I program for TRV734.
